Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + gabapentin
- Development stage
- Unknown
- Lead developer
- Beni-Suef University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Duloxetine + gabapentin is a combination therapy being investigated by Beni-Suef University for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the synaptic concentration of serotonin and norepinephrine, thereby enhancing descending inhibitory pain control in the central nervous system. Gabapentin is a gabapentinoid that binds with high affinity to the alpha-2-delta-1 subunit of voltage-gated calcium channels, leading to a reduction in the calcium-dependent release of pro-nociceptive neurotransmitters. This combination approach aims to target multiple mechanisms of neuropathic pain to achieve superior efficacy compared to monotherapy in cancer patients suffering from CIPN.
- Other names
- Duloxetine augmented with gabapentin
02
Targets
SERT (Sodium-dependent serotonin transporter)SCN9A (Sodium channel protein type 9 subunit alpha)DAT (Dopamine plasma membrane transport protein)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on duloxetine + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + gabapentin.